Skip to main content
U.S. flag

An official website of the United States government

Here’s how you know

.gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

HTTPS

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms during this transition.

Clinicalinfo.HIV.gov logo.
In affiliation with HIV.gov
Main navigation
  • Home
  • About
  • Guidelines
  • Drug Database
  • Glossary
  • News
  • Resources
  • Contact Us
  • English
  • Español (Spanish)
  1. Home
  2. Guidelines search

Search Guidelines

  • Perinatal HIV Clinical Guidelines (41)
  • HIV Clinical Guidelines: Adult and Adolescent ARV (36)
  • HIV Clinical Guidelines: Pediatric ARV (36)
  • HIV Clinical Guidelines: Adult and Adolescent Opportunistic Infections (14)
  • HIV Clinical Guidelines: Pediatric Opportunistic Infections (6)
  • Guidance for Caring for People With HIV Displaced by Disasters (2)
Search Results 41 – 60 of 135
Special Considerations for Antiretroviral Therapy Use in Adolescents With HIV
… Many ARV drugs (e.g., abacavir, emtricitabine, lamivudine, tenofovir disoproxil fumarate [TDF], some protease …
Suboptimal CD4 Cell Recovery Despite Viral Suppression
… al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and …
Interruption of Antiretroviral Therapy
… bridging was used for those on LA ART. If interruption of tenofovir (TFV)-containing ART is necessary in people with …
Hepatitis B Virus Infection
… routine HBV DNA testing is not recommended. However, if a tenofovir-sparing HIV regimen is being considered, some … people with HIV/HBV coinfection (median age 41 years) on tenofovir-containing antiretroviral therapy (ART), the … yearly (AIII). Special Considerations When Initiating Tenofovir-Sparing ARV Regimens In people without a history …
Hepatitis C Virus Infection
… the following: Velpatasvir can increase concentrations of tenofovir disoproxil fumarate and lead to tenofovir-related renal toxicity. It is unclear at this time whether this is also the case with tenofovir alafenamide. Nevertheless, care should be taken in …
Immune Activation and Inflammation Among People With HIV Receiving Antiretroviral Therapy
… density after initiation of antiretroviral treatment with tenofovir disoproxil fumarate/emtricitabine plus …
Optimizing Antiretroviral Therapy in the Setting of Viral Suppression
… NRTI = nucleoside reverse transcriptase inhibitor; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate With currently available … switching to an ARV regimen that does not include tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate …
Preventing HIV Transmission During Infant Feeding
… infant. 92 NRTIs show more variability than PIs and NNRTIs. Tenofovir concentrations from tenofovir disoproxil fumarate (TDF) are very low in breast … Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk …
Herpes Simplex Virus
… . Abdool Karim SS, Abdool Karim Q, Kharsany AB, et al. Tenofovir gel for the prevention of herpes simplex virus …
Overview
… caused by atazanavir, renal tubulopathy caused by tenofovir disoproxil fumarate) usually can be managed by … . Hill A, Hughes SL, Gotham D, Pozniak AL. Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in …
Central Nervous System Toxicity
… al. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: … tolerability of bictegravir combined with emtricitabine/tenofovir alafenamide in clinical practice. Antivir Ther . … co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir DF versus continuation of non-nucleoside reverse …
Dyslipidemia
… in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other … N, Margusino-Framinan L, et al. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with …
Special Populations: HIV-2 Infection
… controlled trial comparing raltegravir (RAL) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) to … D, Gallien S, et al. First-line raltegravir/emtricitabine/tenofovir combination in human immunodeficiency virus type 2 … regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate for the initial treatment of …
Cardiovascular Complications in People With HIV
… of a first MACE with ART regimens, including ABC versus tenofovir-containing regimens, 32 and an increased MACE … (HDL), and triglycerides have been observed with tenofovir alafenamide (TAF), efavirenz (EFV), all boosted … who received TAF when compared with those who received tenofovir disoproxil fumarate (TDF) in multiple randomized …
Special Populations: HIV and the Older Person
… to the marked fracture risk. ART regimens that contain tenofovir disoproxil fumarate (TDF), 27 boosted protease … (INSTIs). 28-31 Abacavir (ABC), NRTI-sparing regimens, and tenofovir alafenamide (TAF) may be considered as … density after initiation of antiretroviral treatment with tenofovir disoproxil fumarate/emtricitabine plus …
Weight Gain in People With Treated HIV
… reverse transcriptase inhibitor (NNRTI)–based and tenofovir disoproxil fumarate (TDF)–based regimens. 6-9 … and the nucleotide reverse transcriptase inhibitor (NRTI) tenofovir alafenamide (TAF), 11,13 especially when compared … . Lake JE, Trevillyan J. Impact of Integrase inhibitors and tenofovir alafenamide on weight gain in people with HIV. …
Lactic Acidosis
… acidosis after concomitant treatment with metformin and tenofovir in a patient with HIV infection. J Ren Care . … M, Matsumoto M, Sawamura M. Severe lactic acidosis during tenofovir disoproxil fumarate and cobicistat combination for … Whitsett M, Papadopoulos Z, et al. Successful treatment of tenofovir alafenamide-induced lactic acidosis: a case …
Lipodystrophies and Weight Gain
… Infections Cohort Collaboration Study G. Weight gain on tenofovir alafenamide fumarate-based therapy compared to tenofovir disoproxil fumarate- and abacavir-based therapy in … Townsend CL, Milanzi E, et al. Effectiveness and safety of tenofovir alafenamide in children and adolescents living …
Nephrotoxic Effects
… . Campbell L, Barbini B, Cromarty B, et al. Safety of tenofovir alafenamide in people with HIV who experienced proximal renal tubulopathy on tenofovir. AIDS. 2024;38(9):1442-1445. Available at: … . Gupta SK, Post FA, Arribas JR, et al. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a …
Osteopenia and Osteoporosis
… S, et al. Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed … B, Wang S, Cheung AM, Mishra S, Tan DH. The effect of tenofovir disoproxil fumarate on bone mineral density: a … X, et al. Vitamin D and calcium supplementation reverses tenofovir-caused bone mineral density loss in people taking …

Pagination

  • First page ‹‹
  • Previous page ‹
  • Page 1
  • Page 2
  • Current page 3
  • Page 4
  • Page 5
  • …
  • Next page ›
  • Last page ››

CONNECT WITH US

Footer menu

  • Home
  • About
  • Guidelines
  • Drug Database
  • Glossary
  • News
  • Resources
  • Contact Us
  • Sponsors
  • Nondiscrimination Notice
  • Accessibility
  • Disclaimers
  • Sitemap
  • Privacy Policy
  • HHS Vulnerability Disclosure

External links

  • HIVinfo.NIH.gov
  • HHS.gov
  • NIH.gov
  • Players & Viewers
  • HHS 508
  • HHS Privacy Policy
  • Whitehouse.gov
  • USA.gov
  • Freedom of Information Act

Provided in collaboration with NIH’s Office of AIDS Research.